DK1417300T3 - Proces til modning af dendritceller og en vaccine - Google Patents

Proces til modning af dendritceller og en vaccine

Info

Publication number
DK1417300T3
DK1417300T3 DK02758675T DK02758675T DK1417300T3 DK 1417300 T3 DK1417300 T3 DK 1417300T3 DK 02758675 T DK02758675 T DK 02758675T DK 02758675 T DK02758675 T DK 02758675T DK 1417300 T3 DK1417300 T3 DK 1417300T3
Authority
DK
Denmark
Prior art keywords
poly
dendritic cells
gxu
cxu
vaccine
Prior art date
Application number
DK02758675T
Other languages
Danish (da)
English (en)
Inventor
Malcolm Adams
Cyril Donninger
Original Assignee
Bioclones Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclones Pty Ltd filed Critical Bioclones Pty Ltd
Application granted granted Critical
Publication of DK1417300T3 publication Critical patent/DK1417300T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02758675T 2001-08-08 2002-08-08 Proces til modning af dendritceller og en vaccine DK1417300T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119346.5A GB0119346D0 (en) 2001-08-08 2001-08-08 Process for the maturation of dendritic cells

Publications (1)

Publication Number Publication Date
DK1417300T3 true DK1417300T3 (da) 2006-07-17

Family

ID=9920030

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02758675T DK1417300T3 (da) 2001-08-08 2002-08-08 Proces til modning af dendritceller og en vaccine

Country Status (14)

Country Link
US (1) US7981673B2 (ja)
EP (1) EP1417300B1 (ja)
JP (1) JP2004538000A (ja)
AT (1) ATE320481T1 (ja)
AU (1) AU2002324255B2 (ja)
BR (1) BR0212016A (ja)
CA (1) CA2457322C (ja)
DE (1) DE60209915T2 (ja)
DK (1) DK1417300T3 (ja)
ES (1) ES2263806T3 (ja)
GB (1) GB0119346D0 (ja)
MX (1) MXPA04001152A (ja)
WO (1) WO2003014335A1 (ja)
ZA (1) ZA200401842B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
WO2005043155A1 (en) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
AU2013206335B2 (en) * 2005-12-07 2017-05-04 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
JP2010520284A (ja) * 2007-03-05 2010-06-10 ユタ ステイト ユニバーシティ Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト
WO2009088401A2 (en) * 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
CA2715293A1 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3
CA2722589A1 (en) * 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
CA2740011A1 (en) * 2008-10-10 2010-04-15 Hemispherx Biopharma, Inc. Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
SI2340307T1 (sl) * 2008-10-23 2016-02-29 Hemispherx Biopharma, Inc. Dvoverižne ribonukleinske kisline z robustno fizikalno-kemijsko strukturo in zelo specifično biološko aktivnostjo
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
WO2017152008A1 (en) 2016-03-04 2017-09-08 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
AU2019264232A1 (en) * 2018-05-04 2020-11-12 Tollys TLR3 ligands that activate both epithelial and myeloid cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response

Also Published As

Publication number Publication date
ATE320481T1 (de) 2006-04-15
DE60209915D1 (de) 2006-05-11
ES2263806T3 (es) 2006-12-16
CA2457322C (en) 2014-06-10
DE60209915T2 (de) 2006-12-14
CA2457322A1 (en) 2003-02-20
EP1417300B1 (en) 2006-03-15
ZA200401842B (en) 2005-05-25
WO2003014335A1 (en) 2003-02-20
JP2004538000A (ja) 2004-12-24
GB0119346D0 (en) 2001-10-03
AU2002324255B2 (en) 2007-06-07
US7981673B2 (en) 2011-07-19
EP1417300A1 (en) 2004-05-12
US20040253722A1 (en) 2004-12-16
MXPA04001152A (es) 2005-02-17
BR0212016A (pt) 2004-10-26

Similar Documents

Publication Publication Date Title
DK1417300T3 (da) Proces til modning af dendritceller og en vaccine
US8076068B2 (en) Method for determining immunostimulatory activity of RNA oligonucleotides
CA2513809A1 (en) Lipophilic derivatives of double-stranded ribonucleic acid
IL248493A0 (en) A method for increasing type 1 presentation of exogenous antigens using dendritic cells of human origin
PL1646671T3 (pl) (Met)akrylany eterów oksyalkilenowanych nienasyconych polioli i sposób ich wytwarzania
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
DE60030988D1 (de) Verfahren zur Herstellung Von L-Aminosäuren durch Erhöhung des zellulären NADPH
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
Ishii et al. TLR ignores methylated RNA?
DE502004000547D1 (de) Verfahren zur fermentativen Herstellung von L-Methionin
DE60219501D1 (de) Verfahren zur herstellung von 3-hydroxy-n-1,6-trialkyl-4-oxo-1,4-dihydropyridin-2-carboxamide
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
DE60017375D1 (de) Verfahren zur herstellung eines diols
ATE376562T1 (de) Verfahren zur herstellung von blockcopolymeren
DE60328459D1 (de) Polymerisationsverfahren zur herstellung von syndiotaktischem 1,2-polybutadien
TW200502252A (en) Formulations of modified antibodies and methods of making the same
KR102320269B1 (ko) 돼지생식기호흡기증후군 바이러스의 감염력 향상 또는 억제를 위한 돼지 대식세포 분화 및 극성화 방법
DE50301697D1 (de) Verfahren zur herstellung von polyetheralkoholen
EP1028138A3 (en) Haze free polyether polyol compositions and a method for their preparation
US7981601B2 (en) Method of preparing polyepitope chimeric gene vaccine
WO2002029064A3 (en) Method for establishing germ cell-specific gene expression
Leibovitch et al. Active DNA transcription sites released from the genome of normal embryonic chicken cells
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
DE60016580D1 (de) Verfahren zur herstellung eines diols
CN117264949A (zh) 抑制Apo(a)基因表达的siRNA及其组合物